- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00925301
Study of the Effects of Oral AT1001 (Migalastat Hydrochloride) in Patients With Fabry Disease
A Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy, Safety and Pharmacodynamics of AT1001 in Patients With Fabry Disease and AT1001-Responsive GLA Mutations
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This double-blind, randomized, placebo-controlled study was conducted in 67 participants at 46 sites worldwide. The study consisted of 2 stages and an optional open-label treatment extension phase:
Stage 1 included a screening period of up to 2 months followed by a 6-month treatment period which involved 4 visits to the clinic. Participants were randomized in equal proportions to receive either migalastat or placebo.
After completing the 6-month double-blind phase, all participants entered Stage 2 of the study and received migalastat in an open-label manner. Stage 2 treatment lasted for 6 months and involved up to 4 visits to the clinic.
Participants who completed both Stage 1 and Stage 2 of the study as scheduled were offered the opportunity to participate in an open-label treatment extension phase with migalastat. The open-label treatment extension phase lasted 12 months and involved 2 visits to the clinic. A follow-up visit was undertaken 1 month following completion or discontinuation from the open-label treatment extension. Participants completing the 12-month open-label treatment extension and providing consent to enter a separate long-term extension were not required to complete this follow-up visit.
Study assessments included clinical laboratory tests, 12-lead electrocardiogram, kidney biopsy, kidney function testing, echocardiography, and patient-reported outcomes.
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Buenos Aires, Argentina, B1629ODT
-
-
-
-
-
Adelaide, Australia, 5006
-
Parkville, Australia, 3050
-
-
-
-
-
Porto Alegre, Brazil, 90035-903
-
Sao Paulo, Brazil, 14048-900
-
-
-
-
Quebec
-
Montreal, Quebec, Canada, H4J 1C5
-
-
-
-
-
Kobenhavn, Denmark, DK-2100
-
-
-
-
-
Cairo, Egypt, 11451
-
-
-
-
-
Garches, France, 92380
-
-
-
-
-
Roma, Italy, 00168
-
-
-
-
-
Warszawa, Poland, 04-628
-
-
-
-
-
Barcelona, Spain, 08025
-
Zaragoza, Spain, 50009
-
-
-
-
-
Ankara, Turkey, 06500
-
-
-
-
-
Salford, United Kingdom, M6 8HD
-
-
-
-
California
-
Los Angeles, California, United States, 90048
-
San Francisco, California, United States, 94143
-
-
Georgia
-
Decatur, Georgia, United States, 30033
-
-
Illinois
-
Chicago, Illinois, United States, 60611
-
-
Kansas
-
Kansas City, Kansas, United States, 66160
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02114
-
-
Michigan
-
Grand Rapids, Michigan, United States, 49525
-
-
New York
-
New York, New York, United States, 10032
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, United States, 15224
-
-
Texas
-
Dallas, Texas, United States, 75226
-
-
Utah
-
Salt Lake City, Utah, United States, 84132
-
-
Virginia
-
Springfield, Virginia, United States, 22152
-
-
Washington
-
Seattle, Washington, United States, 98195
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Male or female between the ages of 16 and 74 diagnosed with Fabry disease.
- Confirmed mutant form of α-galactosidase A shown to be responsive to migalastat in vitro.
- Participant has never been treated with enzyme replacement therapy (ERT) or has not received ERT for 6 consecutive months or longer before the screening visit for the study.
- Urine GL-3 ≥4 times the upper limit of normal at screening.
- Participants taking angiotensin converting enzyme inhibitors or angiotensin receptor blockers must be on a stable dose for a minimum of 4 weeks before the baseline visit.
- Females who can become pregnant and all males agree to be sexually abstinent or use medically accepted methods of birth control during the study and for 30 days after study completion.
- Participant is willing and able to provide written informed consent and assent, if applicable.
Exclusion Criteria:
- Participant has undergone or is scheduled to undergo kidney transplantation, or is currently on dialysis.
- Estimated glomerular filtration rate <30 milliliters per minute per 1.73 meters squared (chronic kidney disease Stage 4 or 5) based on the Modification of Diet in Renal Disease equation at screening.
- Pregnant or breast-feeding.
- History of allergy or sensitivity to study medication (including excipients) or other iminosugars (for example, miglustat, miglitol).
- Participant is treated or has been treated with any investigational drug within 30 days of study start.
- Participant is currently treated or has ever been treated with migalastat.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: DOUBLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Migalastat
Migalastat 150-mg capsule taken orally every other day (QOD) for 6 months and an open-label 6-month treatment extension, followed by an optional, 12-month, open-label treatment extension.
|
Oral capsule QOD
Other Names:
|
PLACEBO_COMPARATOR: Placebo
Placebo capsule taken orally QOD for 6 months.
|
Oral capsule QOD
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage Of Participants With At Least A 50% Reduction From Baseline To Month 6 In The Average Number Of Kidney Interstitial Capillary (IC) Globotriaosylceramide (GL-3) Inclusions
Time Frame: Baseline, Month 6
|
Renal biopsies were taken at Baseline and Month 6 (Stage 1).
The specimens were evaluated using virtual microscopy.
The annotation, scoring, and adjudication of the kidney histology assessments were performed by the Clinical Pathology Endpoints Committee.
The number of kidney IC GL-3 inclusions was assessed by 3 renal pathologists who were blinded to treatment assignments, participants' data, and biopsy sequence.
One pathologist served as annotator and identified the 300 capillaries on up to 8 slides per specimen to be scored.
Two pathologists served as scorers; these pathologists completed the blinded paired assessments.
Each pathologist served as annotator/adjudicator for 1/3 of the cases.
Paired assessments were undertaken at Baseline and Month 6. Assessments were made using digital images.
A responder was defined as a participant with a ≥50% reduction from Baseline to Month 6 in the average number of kidney IC GL-3 inclusions.
|
Baseline, Month 6
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percent Change In Kidney IC GL-3 Inclusions From Baseline To Month 6
Time Frame: Baseline, Month 6
|
Renal biopsies were taken at Baseline and Month 6.
The specimens were evaluated using virtual microscopy.
The annotation, scoring, and adjudication of the kidney histology assessments were performed by the Clinical Pathology Endpoints Committee.
The number of kidney IC GL-3 inclusions was assessed by 3 renal pathologists who were blinded to treatment assignments, participants' data, and biopsy sequence.
One pathologist served as annotator and identified the 300 capillaries on up to 8 slides per specimen to be scored.
Two pathologists served as scorers; these pathologists completed the blinded paired assessments.
Each pathologist served as annotator/adjudicator for 1/3 of the cases.
Paired assessments were undertaken at Baseline and Month 6. Assessments were made using digital images.
|
Baseline, Month 6
|
Change From Baseline Through Month 24 In Urine GL-3 Levels
Time Frame: Baseline, Months 6, 12, and 24
|
The effect of migalastat versus placebo on urine GL-3 levels was measured by liquid chromatography-mass spectrometry/mass spectrometry.
The 24-hour urine samples were collected at Baseline, Month 6 (Stage 1), Month 12 (Stage 2), and Month 24 (OLE).
Results are presented as changes in nanograms (ng)/mg creatinine from Baseline to the end of the 3 stages.
|
Baseline, Months 6, 12, and 24
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change From Month 6 To Month 12 In Average Number Of Kidney IC GL-3 Inclusions
Time Frame: Month 6, Month 12
|
Renal biopsies were taken at Month 6 and Month 12.
The specimens were evaluated using virtual microscopy.
The annotation, scoring, and adjudication of the kidney histology assessments were performed by the Clinical Pathology Endpoints Committee.
The number of kidney IC GL-3 inclusions was assessed by 3 renal pathologists who were blinded to treatment assignments, participants' data, and biopsy sequence.
One pathologist served as annotator and identified the 300 capillaries on up to 8 slides per specimen to be scored.
Two pathologists served as scorers; these pathologists completed the blinded paired assessments.
Each pathologist served as annotator/adjudicator for 1/3 of the cases.
Paired assessments were undertaken at Month 6 and Month 12. Assessments were made using digital images.
|
Month 6, Month 12
|
Collaborators and Investigators
Sponsor
Publications and helpful links
General Publications
- Bichet DG, Aerts JM, Auray-Blais C, Maruyama H, Mehta AB, Skuban N, Krusinska E, Schiffmann R. Assessment of plasma lyso-Gb3 for clinical monitoring of treatment response in migalastat-treated patients with Fabry disease. Genet Med. 2021 Jan;23(1):192-201. doi: 10.1038/s41436-020-00968-z. Epub 2020 Sep 30. Erratum In: Genet Med. 2020 Nov 20;:
- Germain DP, Nicholls K, Giugliani R, Bichet DG, Hughes DA, Barisoni LM, Colvin RB, Jennette JC, Skuban N, Castelli JP, Benjamin E, Barth JA, Viereck C. Efficacy of the pharmacologic chaperone migalastat in a subset of male patients with the classic phenotype of Fabry disease and migalastat-amenable variants: data from the phase 3 randomized, multicenter, double-blind clinical trial and extension study. Genet Med. 2019 Sep;21(9):1987-1997. doi: 10.1038/s41436-019-0451-z. Epub 2019 Feb 6.
- Schiffmann R, Bichet DG, Jovanovic A, Hughes DA, Giugliani R, Feldt-Rasmussen U, Shankar SP, Barisoni L, Colvin RB, Jennette JC, Holdbrook F, Mulberg A, Castelli JP, Skuban N, Barth JA, Nicholls K. Migalastat improves diarrhea in patients with Fabry disease: clinical-biomarker correlations from the phase 3 FACETS trial. Orphanet J Rare Dis. 2018 Apr 27;13(1):68. doi: 10.1186/s13023-018-0813-7.
- Benjamin ER, Della Valle MC, Wu X, Katz E, Pruthi F, Bond S, Bronfin B, Williams H, Yu J, Bichet DG, Germain DP, Giugliani R, Hughes D, Schiffmann R, Wilcox WR, Desnick RJ, Kirk J, Barth J, Barlow C, Valenzano KJ, Castelli J, Lockhart DJ. The validation of pharmacogenetics for the identification of Fabry patients to be treated with migalastat. Genet Med. 2017 Apr;19(4):430-438. doi: 10.1038/gim.2016.122. Epub 2016 Sep 22.
- Germain DP, Hughes DA, Nicholls K, Bichet DG, Giugliani R, Wilcox WR, Feliciani C, Shankar SP, Ezgu F, Amartino H, Bratkovic D, Feldt-Rasmussen U, Nedd K, Sharaf El Din U, Lourenco CM, Banikazemi M, Charrow J, Dasouki M, Finegold D, Giraldo P, Goker-Alpan O, Longo N, Scott CR, Torra R, Tuffaha A, Jovanovic A, Waldek S, Packman S, Ludington E, Viereck C, Kirk J, Yu J, Benjamin ER, Johnson F, Lockhart DJ, Skuban N, Castelli J, Barth J, Barlow C, Schiffmann R. Treatment of Fabry's Disease with the Pharmacologic Chaperone Migalastat. N Engl J Med. 2016 Aug 11;375(6):545-55. doi: 10.1056/NEJMoa1510198.
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Cardiovascular Diseases
- Vascular Diseases
- Metabolic Diseases
- Cerebrovascular Disorders
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Genetic Diseases, Inborn
- Genetic Diseases, X-Linked
- Metabolism, Inborn Errors
- Lysosomal Storage Diseases
- Lipid Metabolism Disorders
- Brain Diseases, Metabolic
- Brain Diseases, Metabolic, Inborn
- Sphingolipidoses
- Lysosomal Storage Diseases, Nervous System
- Cerebral Small Vessel Diseases
- Lipidoses
- Lipid Metabolism, Inborn Errors
- Fabry Disease
Other Study ID Numbers
- AT1001-011
- FACETS (OTHER: Amicus Therapeutics)
- 2009-013459-31 (EUDRACT_NUMBER)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Fabry Disease
-
CENTOGENE GmbH RostockCompletedFabry Disease | Anderson-Fabry Disease | Fabry´s DiseaseArgentina, Belgium, Croatia, Czechia, Denmark, France, Germany, United Kingdom
-
Wuerzburg University HospitalTakedaEnrolling by invitationLysosomal Storage Diseases | Fabry Disease | Fabry Disease, Cardiac Variant | HCM - Hypertrophic Cardiomyopathy | Anderson Fabry DiseaseGermany
-
University Hospital, RouenUnknownAnderson-Fabry DiseaseFrance
-
Sangamo TherapeuticsEnrolling by invitationFabry Disease | Fabry Disease, Cardiac VariantUnited States, Australia, United Kingdom
-
Amicus Therapeutics France SASActive, not recruitingFabry Disease | Anderson Fabry DiseaseFrance
-
Academisch Medisch Centrum - Universiteit van Amsterdam...RecruitingFabry Disease | Fabry Disease, Cardiac VariantNetherlands
-
Taipei Veterans General Hospital, TaiwanSanofiUnknownFabry Disease, Cardiac Variant
-
University of CambridgeSanofiRecruiting
-
Shaare Zedek Medical CenterJohannes Gutenberg University MainzCompleted
-
Wolfson Medical CenterUnknownFabry Disease in the Young StrokeIsrael
Clinical Trials on migalastat hydrochloride
-
Amicus TherapeuticsTerminatedFabry DiseaseAustralia, United States, Italy, Spain, Belgium, Turkey, Brazil, Argentina, United Kingdom, Denmark, France, Canada, Egypt
-
Amicus TherapeuticsCompletedFabry DiseaseFrance, Austria, United States, Belgium, Japan, United Kingdom, Denmark, Brazil, Australia, Italy
-
Amicus TherapeuticsApproved for marketingPhysician Initiated Expanded Access Request for Migalastat in Individual Patients With Fabry DiseaseFabry DiseaseUnited States, Australia
-
Amicus TherapeuticsRecruitingFabry DiseaseSpain, United States, Japan, Australia, France, Portugal
-
Amicus TherapeuticsActive, not recruitingFabry DiseaseUnited States, United Kingdom
-
Amicus TherapeuticsRecruiting
-
Amicus TherapeuticsCompletedFabry DiseaseAustralia, Brazil
-
Amicus TherapeuticsCompletedFabry DiseaseUnited States
-
Amicus TherapeuticsTerminatedFabry DiseaseUnited Kingdom, United States, Australia, Brazil, France